Insider trading

Period: 120 months Stock: XENE + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

91 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

91 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

91 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

91 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
91 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
91 decisions over 120 months
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

91 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
30 Sep 2026
MORTIMER IAN PRESIDENT & CEO
Bought
$1.12M 30,000 at 37.38
151%
First buy on file
30 Sep 2026
Kelly Thomas Patrick Chief Financial Officer
Bought
$559.74K 15,000 at 37.32
opened
First buy on file
28 Aug 2026
KENNEY CHRISTOPHER JOHN Chief Medical Officer
Sold on a plan 2×
$425.83K 7,068 at 60.25
100.0%
Sold half or more
11 Aug 2026
GANNON STEVEN Director
Sold at will
$640.55K 10,000 at 64.06
84.2%
Sold half or more
5 Jun 2026
PATOU GARY Director
Sold on a plan
$70.25K 1,322 at 53.14
5.0%
Planned (10b5-1)
5 Jun 2026
Cannon Gillian Director
Sold on a plan
$63.24K 1,190 at 53.14
45.0%
Planned (10b5-1)
13 Mar 2026
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$403.58K 7,308 at 55.23
26.8%
Planned (10b5-1)
13 Mar 2026
KENNEY CHRISTOPHER JOHN Chief Medical Officer
Sold on a plan
$77.87K 1,410 at 55.23
16.6%
Planned (10b5-1)
13 Mar 2026
DiFabio Andrea Chief Legal Officer
Sold on a plan
$74.11K 1,342 at 55.23
15.5%
Planned (10b5-1)
10 Mar 2026
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$677.36K 11,269 at 60.11
43.3%
Planned (10b5-1)
10 Mar 2026
KENNEY CHRISTOPHER JOHN Chief Medical Officer
Sold on a plan
$166.56K 2,771 at 60.11
36.9%
Planned (10b5-1)
10 Mar 2026
DiFabio Andrea Chief Legal Officer
Sold on a plan
$156.70K 2,607 at 60.11
34.8%
Planned (10b5-1)
9 Mar 2026
MORTIMER IAN PRESIDENT & CEO
Sold on a plan 9×
$16.29M 270,000 at 60.33
97.8%
Sold half or more
2 Jan 2026
MORTIMER IAN PRESIDENT & CEO
Sold on a plan 2×
$1.78M 40,000 at 44.43
87.0%
Sold half or more
8 Dec 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan 2×
$495.21K 10,830 at 45.73
64.3%
Sold half or more
5 Dec 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$647.31K 14,375 at 45.03
46.1%
Planned (10b5-1)
28 Nov 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$4.37K 97 at 45.01
0.3%
Planned (10b5-1)
1 Oct 2025
MORTIMER IAN PRESIDENT, CEO & INTERIM CFO
Sold on a plan
$1.00M 25,000 at 40.16
44.4%
Planned (10b5-1)
5 Jun 2025
GANNON STEVEN Director
Sold at will
$91.44 3 at 30.48
0.0%
Not planned
27 Jan 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan 2×
$660.81K 16,315 at 40.50
34.3%
Planned (10b5-1)
24 Jan 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$903.21K 22,468 at 40.20
41.8%
Planned (10b5-1)
23 Jan 2025
MORTIMER IAN PRESIDENT & CEO
Sold on a plan
$649.98K 16,217 at 40.08
34.1%
Planned (10b5-1)
18 Dec 2024
AULIN SHERRY Chief Financial Officer
Sold at will 2×
$770.91K 18,709 at 41.21
100%
Sold half or more
22 Nov 2024
PATOU GARY Director
Sold at will 2×
$200.95K 4,891 at 41.08
17.2%
Not planned
8 Mar 2024
Sold at will
$95.58K 2,092 at 45.69
100%
Sold half or more
7 Mar 2024
GANNON STEVEN Director
Sold at will 4×
$601.61K 13,000 at 46.28
86.7%
Sold half or more
7 Mar 2024
ROBIN SHERRINGTON EVP, Strategy & Innovation
Sold at will 2×
$330.29K 7,137 at 46.28
45.9%
Not planned
13 Dec 2023
PATOU GARY Director
Sold at will 3×
$447.08K 11,380 at 39.29
32.6%
Not planned
13 Dec 2023
PATOU GARY Director · indirect
Sold at will
$311.90K 7,598 at 41.05
60.8%
Sold half or more
24 Aug 2023
Svoronos Dawn Director
Sold at will
$967.50K 25,000 at 38.70
50.0%
Sold half or more
1 Jun 2023
Sold at will 2×
$1.23M 31,713 at 38.82
84.1%
Sold half or more
31 May 2023
Sold at will 3×
$2.42M 62,526 at 38.70
91.2%
Sold half or more
30 May 2023
Sold at will 2×
$1.45M 37,006 at 39.28
67.3%
Sold half or more
24 May 2023
MORTIMER IAN PRESIDENT & CEO
Sold at will 3×
$1.31M 31,655 at 41.41
56.7%
Sold half or more
24 Mar 2023
KENNEY CHRISTOPHER JOHN Chief Medical Officer
Sold at will
$24.51K 700 at 35.01
100%
Sold half or more
7 Mar 2023
Sold, plan not stated 2×
$711.20K 19,232 at 36.98
36.1%
25 Nov 2022
PATOU GARY Director
Sold, plan not stated
$67.39K 1,937 at 34.79
7.6%
23 Nov 2022
PATOU GARY Director
Sold, plan not stated
$70.61K 2,057 at 34.33
8.0%
2 Sep 2022
AULIN SHERRY Chief Financial Officer
Sold, plan not stated
$607.60K 15,355 at 39.57
100%
Sold half or more
1 Sep 2022
ROBIN SHERRINGTON EVP, Strategy & Innovation
Sold, plan not stated 2×
$1.68M 43,879 at 38.18
72.3%
Sold half or more
31 Aug 2022
ROBIN SHERRINGTON EVP, Strategy & Innovation
Sold, plan not stated
$823.55K 21,352 at 38.57
56.0%
Sold half or more
16 Aug 2022
Sold, plan not stated 2×
$2.00M 52,058 at 38.51
89.7%
Sold half or more
15 Aug 2022
Sold, plan not stated
$1.28M 33,942 at 37.76
36.9%
12 Aug 2022
Sold, plan not stated 3×
$3.49M 91,135 at 38.28
49.8%
12 Aug 2022
EMPFIELD JAMES R. EVP, Drug Discovery
Sold, plan not stated 2×
$2.21M 57,743 at 38.31
85.2%
Sold half or more
8 Mar 2022
Sold, plan not stated 6×
$375.64K 14,551 at 25.82
7.4%
7 Mar 2022
EMPFIELD JAMES R. EVP, Drug Discovery
Sold, plan not stated 2×
$1.00M 32,853 at 30.54
76.7%
Sold half or more
7 Mar 2022
Sold, plan not stated 7×
$948.26K 31,086 at 30.50
13.6%
4 Mar 2022
ROBIN SHERRINGTON EVP, Strategy & Innovation
Sold, plan not stated 4×
$662.21K 21,710 at 30.50
55.7%
Sold half or more
4 Mar 2022
EMPFIELD JAMES R. EVP, Drug Discovery
Sold, plan not stated
$563.92K 18,315 at 30.79
64.7%
Sold half or more
Showing 1–50 of 91. Page 1 of 2 Older →